Navigation Links
Reassuring evidence: Anticancer drug does not accelerate tumor growth after treatment ends
Date:2/7/2013

Studies in animals have raised concerns that tumors may grow faster after the anticancer drug sunitinib is discontinued. But oncologists and physicists who collaborated to analyze data from the largest study of patients with kidney cancer convincingly demonstrate that such tumor acceleration does not occur in humans. The findings, publishing online on February 7th in the Cell Press journal Cell Reports, suggest that sunitinib does not cause lingering risks for patients after their treatment ends.

"We were able to demonstrate that this applied across all patients and that those who had the greatest benefit from the drug while it was administered retained this benefit," says senior author Dr. Tito Fojo, of the National Cancer Institute at the National Institutes of Health.

Sunitinib, which is approved around the world for the treatment of several different cancers, works by targeting proteins on the blood vessels that feed tumors. Animal studies have suggested that treatment with sunitinib may induce changes in tumor vessels or adaptations within tumors themselves that could promote cancer growth and spread.

When Dr. Fojo and his colleagues analyzed more than 10,000 data points from the pivotal randomized phase 3 clinical trial that led to sunitinib's approval, the evidence clearly showed that no matter how long patients took sunitinib, it was not harmful, did not accelerate tumor growth, and did not shorten survival after treatment ended. During treatment, the drug slowed tumor growth and prolonged the patients' survival.

"Last year, I was approached by two patients who had grave concerns about taking sunitinib due to an article conducted in animals. I realized that if clinical data exist that refute basic science, they must be published," recalls Dr. Fojo.

The researchers' findings indicate that sunitinib can benefit patients without altering tumor biology after the drug is stopped. "We hope this can be ge
'/>"/>

Contact: Mary Beth OLeary
moleary@cell.com
617-397-2802
Cell Press
Source:Eurekalert  

Page: 1 2

Related medicine news :

1. Potential new technique for anticancer radiotherapy could provide alternative to brachytherapy
2. Taiho Pharmaceutical unveils data on 8 novel anticancer compounds
3. Enzyme accelerates malignant stem cell cloning in chronic myeloid leukemia
4. Fat Loss 4 Idiots: Review Examining New "Accelerated Fat Loss Diet" Released By DietsAndFitnessGuides.com
5. EzW2 Software From Halfpricesoft.com Updated To Accelerate Tax Reporting For Startups
6. Studying marrow, URMC researchers accelerate blood stem cells
7. Topical simvastatin shown to accelerate wound healing in diabetes
8. Concussions and head impacts may accelerate brain aging
9. Accelerated resolution therapy significantly reduces PTSD symptoms, researchers report
10. Higher energies for laser-accelerated particles possible
11. Accelerated radiation treatment effective for noninvasive breast cancer
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Reassuring evidence: Anticancer drug does not accelerate tumor growth after treatment ends
(Date:4/1/2015)... 01, 2015 OSF Saint Paul Medical ... System , was welcomed into the Ministry April 1, ... Msgr. Paul E. Showalter, vicar general of the Catholic ... Dedication culminated a nearly year-long transition process for the ... hospital. Speakers for the morning ceremony included Sister Judith ...
(Date:4/1/2015)... April 01, 2015 Like a mosaic ... the scientific understanding of the potential causes of rosacea. ... the National Rosacea Society (NRS) to educate the public ... facial disorder now estimated to affect more than 16 ... medical research on rosacea through its patient-funded research grants ...
(Date:4/1/2015)... 2015 eMindful , the provider ... its executive team with the addition of veteran digital ... , In his new role, Suissa is leading ... across the business and consumer portals. He also is ... company’s online community. His hiring was a result ...
(Date:4/1/2015)... (PRWEB) April 01, 2015 When annoying ... occur, waiting days or weeks for an appointment with ... same and next day appointments haven’t been possible within ... Forefront Dermatology’s offices have noticed demand for this level ... “We realize how important relief or answers to dermatological ...
(Date:4/1/2015)... EB Medicine, leading publisher of clinical ... and Hospital Medicine Practice, is pleased to announce ... the content from its flagship publication, Emergency ... available on iPhones, iPads and Android smartphones and ... develop mobile applications for EB Medicine’s journals is ...
Breaking Medicine News(10 mins):Health News:Mendota Community Hospital Now OSF Saint Paul Medical Center 2Health News:Mendota Community Hospital Now OSF Saint Paul Medical Center 3Health News:It’s Becoming Clear: Rosacea Awareness Month Highlights Potential Causes of Rosacea 2Health News:It’s Becoming Clear: Rosacea Awareness Month Highlights Potential Causes of Rosacea 3Health News:It’s Becoming Clear: Rosacea Awareness Month Highlights Potential Causes of Rosacea 4Health News:It’s Becoming Clear: Rosacea Awareness Month Highlights Potential Causes of Rosacea 5Health News:Addressing The Growing Demand for Interactive, Internet Mindfulness Programs, eMindful Expands Leadership Team With Top Digital Marketing Executive 2Health News:Addressing The Growing Demand for Interactive, Internet Mindfulness Programs, eMindful Expands Leadership Team With Top Digital Marketing Executive 3Health News:Dermatology Associates of Wisconsin and Forefront Dermatology Answers Patients' Needs With Unmatched Availability In Sheboygan and Sheboygan Falls 2Health News:EB Medicine Partners With AgileMD on Mobile Application for Emergency Medicine Clinicians 2Health News:EB Medicine Partners With AgileMD on Mobile Application for Emergency Medicine Clinicians 3
... ... PHILADELPHIA, Pennsylvania, November 30 , ... Healthcare Reform and ARRA Momentum , Elsevier, a ... (EHR) integrated solutions, today,announced a new online resource center for American Recovery ...
... The U.S. Centers for Disease Control and Prevention estimate ... States are infected with HIV/AIDS. New research from North ... are minorities and do not have health insurance, and ... education and prevention efforts in minority and low-income populations. ...
... of Navarra Hospital has launched a series of clinical ... immunotherapy treatment. This approach involves the application of personalised ... patient him or herself and designed to combat glioblastomas, ... The new therapy is administered to participating patients combined ...
... heavily more often than younger people, study finds, , MONDAY, ... drinkers consume more alcohol than their younger counterparts, a new ... the same effect. , According to a study released ... 60 consume more than 40 drinks a week, on average. ...
... , SHENZHEN, China, Nov. 30 /PRNewswire-FirstCall/ - ... Mellow Hope finalized contract details with one of the largest ... increase in revenues for Hard to Treat Diseases in the ... company secures the supply of raw pharmaceutical material to the ...
... , ROCKLAND, Mass., Nov. 30 EMD Serono, an ... received a refuse to file letter from the US Food ... for Cladribine Tablets, EMD Serono,s proprietary investigational oral formulation of ... (MS). , "The company will work closely with the ...
Cached Medicine News:Health News:Elsevier Launches New Online ARRA Resource Center and Clinical Decision Support Blog 2Health News:Elsevier Launches New Online ARRA Resource Center and Clinical Decision Support Blog 3Health News:Elsevier Launches New Online ARRA Resource Center and Clinical Decision Support Blog 4Health News:Research highlights need for national HIV strategy 2Health News:Clinical trials launched for treating most aggressive brain tumor with personalized cell vaccines 2Health News:Clinical trials launched for treating most aggressive brain tumor with personalized cell vaccines 3Health News:Clinical trials launched for treating most aggressive brain tumor with personalized cell vaccines 4Health News:Clinical trials launched for treating most aggressive brain tumor with personalized cell vaccines 5Health News:Clinical trials launched for treating most aggressive brain tumor with personalized cell vaccines 6Health News:Binge Drinking Not Just a Rite of the Young 2Health News:Hard to Treat Diseases (HTDS) Closes 1 Million Dollar Contract Indian Pharmaceutical 2Health News:Hard to Treat Diseases (HTDS) Closes 1 Million Dollar Contract Indian Pharmaceutical 3Health News:EMD Serono Receives Refuse to File Letter from FDA on Cladribine Tablets New Drug Application 2Health News:EMD Serono Receives Refuse to File Letter from FDA on Cladribine Tablets New Drug Application 3
(Date:4/1/2015)... 1, 2015 Jintian Pharmaceutical Group Limited ("Jintian ... Mr. Jin Dongtao, chairman and executive director purchased 40,000,000 ... of the existing entire issued share capital of the ... with the total amount of approximately HK$113 million. Upon ... will increase from 45.17% to 47.17%. ...
(Date:4/1/2015)... WALNUT CREEK, Calif. , April 1, 2015 /PRNewswire/ ... a huge difference.  When this is the case, having ... changer.  No one understands this truth better than software ... test laboratory management software QATrax.  Recently, the company announced ... a very enthusiastic response from clients. ...
(Date:4/1/2015)... , April 1, 2015  Egalet Corporation ... specialty pharmaceutical company focused on developing, manufacturing and ... of an offering of $60.0 million aggregate principal ... (the "notes") in a private placement to qualified ... Securities Act of 1933, as amended (the "Act"). ...
Breaking Medicine Technology:Chairman of Jintian Pharmaceutical Purchased Approximately HK$113 Million Worth of Shares Citing Confidence in Company's Development in Online and Offline MacroHealth Business 2Chairman of Jintian Pharmaceutical Purchased Approximately HK$113 Million Worth of Shares Citing Confidence in Company's Development in Online and Offline MacroHealth Business 3Chairman of Jintian Pharmaceutical Purchased Approximately HK$113 Million Worth of Shares Citing Confidence in Company's Development in Online and Offline MacroHealth Business 4Chairman of Jintian Pharmaceutical Purchased Approximately HK$113 Million Worth of Shares Citing Confidence in Company's Development in Online and Offline MacroHealth Business 5TraxStar Technologies Announces Latest QATrax Test Lab Management Software Now Available 2Egalet Announces Proposed $60 Million Offering of Convertible Senior Notes Due 2020 2Egalet Announces Proposed $60 Million Offering of Convertible Senior Notes Due 2020 3Egalet Announces Proposed $60 Million Offering of Convertible Senior Notes Due 2020 4Egalet Announces Proposed $60 Million Offering of Convertible Senior Notes Due 2020 5Egalet Announces Proposed $60 Million Offering of Convertible Senior Notes Due 2020 6Egalet Announces Proposed $60 Million Offering of Convertible Senior Notes Due 2020 7
... of its ongoing,efforts to develop research tools that ... disease, The Michael J. Fox,Foundation announced the launch ... the Foundation seeks to drive the creation,and testing ... with a personal,computer and an Internet connection to ...
... March 19 FluoroPharma Inc., a company,developing breakthrough ... (PET) market, announced commencement of Phase,I clinical trials ... the proposed studies. The Phase I trial is ... safety, distribution and dosimetry,of BFPET as a PET ...
Cached Medicine Technology:New Michael J. Fox Foundation Initiative Will Drive Development of Web-Based Tools to Increase Patient Participation in Parkinson's Clinical Trials 2FluoroPharma Announces Commencement of Phase I Clinical Trial for BFPET(TM), Myocardial Perfusion Imaging (MPI) Tracer for Positron Emission Tomography (PET) 2
... System combines the legendary accuracy of the ... Windows* software. It integrates seamlessly into ... that enhance your clinical capabilities in an ... future of EP. The intended use ...
... combined with a stimulation lead ... Temporary Pacemaker can be used ... pacing is indicated. The device ... as well as diagnostic purposes ...
... offers the world's broadest line of endocardial ... are available in both torque control and ... curve choices and electrode spacing options. ... for use in temporary, transvenous right ventricular ...
... WorldHeart's Novacor LVAS is an ... pulsatile circulatory support for patients ... LVAS has been implanted in ... is the first mechanical circulatory ...
Medicine Products: